R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial.

Andrés J.M. Ferreri,Teresa Calimeri,Gian Marco Conte,Paolo Lopedote,Marco Foppoli,Stefania Girlanda,Angelo Corti,Dario Cattaneo,Federico Fallanca,Alessandro Nonis,Maurilio Ponzoni,Giovanni Citterio,Letterio S. Politi,Marianna Sassone,Salvatore Perrone,Caterina Cecchetti,Fabio Ciceri,Claudio Bordignon,Nicoletta Anzalone

R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial.

2018

Andrés J.M. Ferreri
Teresa Calimeri
Gian Marco Conte
Paolo Lopedote
Marco Foppoli
Stefania Girlanda
Angelo Corti
Dario Cattaneo
Federico Fallanca
Alessandro Nonis
Maurilio Ponzoni
Giovanni Citterio
Letterio S. Politi
Marianna Sassone
Salvatore Perrone
Caterina Cecchetti
Fabio Ciceri
Claudio Bordignon
Nicoletta Anzalone

7575Background: PCNSL pts are treated with HDMTX-based chemo, which requires hospitalization and extensive expertise to manage toxicity. R-CHOP could overcome these troubles, but CNS access of rela...

Keywords:

Refractory
Cancer research
Pathology
Blood–brain barrier
Tumor necrosis factor alpha
Primary CNS Lymphoma
NGR-hTNF
CHOP
Medicine
in patient
Toxicity
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations